$OVIDOvid Therapeutics Inc.

📅 Upcoming

🕒 Recent(90d)

News

• China’s surging biotech sector represents both competition and lifeline for the US
  As Chinese companies push beyond “me-too” drugs and the country lays out a new five-year plan targeting a $522 billion–strong biotech industry by 2030, experts say more predictable funding and regu…
  biospace · 10d ago
• Rare disease reform, CMC risk, reshoring US trials top of mind ahead of PDUFA VIII meeting
  The FDA gathers Wednesday to hear what industry stakeholders and the public want included in the latest iteration of the Prescription Drug User Fee Act that sets the agency’s priorities for fiscal…
  biospace · 18d ago
• For PDUFA VIII, the most valuable incentive may be time
  The FDA’s proposal to offer 50% off application fees for drugs with early-stage trials conducted in the U.S. is unlikely to achieve the intended result. What biotechs really want is speed.
  biospace · 23d ago
• Ovid and Takeda's epilepsy drug gets new life at Perceptive-backed NewCo
  About 26 months after failing two Phase 3 trials, an epilepsy treatment candidate is getting plucked off biopharma's shelves and will be given a new chance at life. Life sciences investment firm Pe…
  endpoints · 1mo ago
• FDA’s leadership void leaves biotech with renewed ‘uncertainty’
  Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.
  biopharma_dive · 4mo ago